Immune reconstitution and severity of COVID-19 among hematopoietic cell transplant recipients

Alexandre E. Malek | Javier A. Adachi | Victor E. Mulanovich | Joseph Sassine | Issam I. Raad | Kelly McConn | Garret T. Seiler | Udit Dhal | Fareed Khawaja | Roy F. Chemaly

Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence
Alexandre E. Malek, Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.
Email: alex.e.malek@gmail.com

Roy F. Chemaly, Professor of Medicine, Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.
Email: rfchemaly@mdanderson.org

Funding information
None.

1 | INTRODUCTION

Coronavirus disease 2019 (COVID-19), secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a worldwide pandemic, presenting unprecedented challenges to health-care providers and systems. The immunopathogenesis of COVID-19 is intriguing as it involves virus-driven tissue damage intertwined with an uncontrolled inflammatory response, contributing to severity of disease, acute respiratory distress syndrome (ARDS), and multiple organ failure. Hematopoietic cell transplant (HCT) recipients are severely immunocompromised, with increased risk of severe COVID-19 secondary to the myeloablative conditioning regimens, organ damage, and possible immune recovery leading to an exuberant inflammatory reaction. A comprehensive approach to manage HCT recipients with COVID-19 at different stages after HCT (pre-engraftment, early and late post-engraftment) is lacking in terms of the potential role of early or pre-emptive antiviral use and/or immunomodulators that may improve clinical outcomes. In this brief report, we present two patients with COVID-19 pneumonia that occurred during the pre-engraftment period after HCT at our comprehensive cancer center. Additionally, we review the previously reported cases of COVID-19 in adults HCT recipients until December 31st, 2020, for whom sufficient data were available.

1.1 | Case 1

A 61-year-old man with multiple myeloma had an autologous HCT after a conditioning regimen consisting of busulfan and melphalan. On admission, the patient was asymptomatic, and a nasopharyngeal (NP) swab yielded negative real-time reverse-transcription polymerase chain reaction (rRT-PCR) results for SARS-CoV-2. On day +3 post-HCT and as part of an investigation of an employees’ cluster of cases, the patient, still asymptomatic, had a NP swab that was positive for COVID-19. Computed tomography (CT) of the chest on day +4 showed no evidence of...
pneumonia (Figure 1A). On day +7, the patient had fevers up to 102°F (38.8°C) and diarrhea that prompted initiation of empiric antibiotics for febrile neutropenia. Further diagnostic workup, including blood cultures, was negative for infectious causes. Repeat chest CT on day +8 revealed new ground-glass opacities (GGOs) suggestive of COVID-19 pneumonia (Figure 1B). Although the patient had persistent fever and positive lung abnormalities, he was not short of breath or hypoxic and did not qualify for remdesivir therapy. He received one dose of tocilizumab (400 mg) on day +10 and a 4-day course of dexamethasone (8 mg daily) starting on day +11 during engraftment for concerns of exuberant inflammatory reaction and engraftment syndrome that could lead to respiratory failure. The patient had a satisfactory clinical recovery with no further complications and was discharged home in stable condition on day +14 after HCT. The salient laboratory studies and clinical course are summarized in Figure 2 (top panel).

1.2 | Case 2

A 69-year-old man with chronic lymphocytic leukemia underwent an allogeneic HCT with a reduced-intensity conditioning regimen (fludarabine and melphalan) and received post-transplant cyclophosphamide for graft-versus-host disease (GvHD) prophylaxis. On admission, the patient was asymptomatic and a NP swab yielded negative rRT-PCR results for SARS-CoV-2. On day +11 after HCT, he developed fever associated with non-productive cough that prompted further diagnostic workup, which included blood cultures that showed Enterococcus faecalis bacteremia, which was likely secondary to mucosal-related bloodstream infection and was treated with vancomycin. A plain X-ray of the chest showed no evidence of pneumonia (Figure 1C). However, in light of persistent fever after 48h of appropriate antibacterial therapy, new onset of cough, and given the concern for a nosocomial acquisition of SARS-CoV-2 infection in the setting of a cluster of employees diagnosed with COVID-19 in the same location, a repeated NP swab on day +13, yielded a positive rRT-PCR results for SARS-CoV-2. A CT scan of the chest showed new bilateral GGOs (Figure 1D). The patient required oxygen supplementation and received convalescent plasma, two doses of tocilizumab (400 mg) on days +16 and +17, methylprednisolone (1 mg/kg) started on day +16, anakinra (100 mg daily) started on day +18, and a 5-day course of remdesivir started on day +19 (day +6 after COVID-19 diagnosis, when it became available at our institution). At day +15 when the patient started engraftment, he required a rapid increase in oxygen supplementation and showed increased bilateral pulmonary opacities (Figure 1E) that led to endotracheal intubation on day +19 and mechanical ventilation. The patient continued worsening and had a severe clinical course and ARDS (Figure 1F), with no improvement. Three weeks after onset of illness and despite full supportive treatment, the patient died. The patient's laboratory studies and clinical course are outlined in Figure 2 (bottom panel).

2 | DISCUSSION

Severe COVID-19 infection has been reported among patients with underlying medical comorbidities such as cardiovascular diseases, hypertension, diabetes mellitus, or cancer and in the elderly people. The spectrum of infection among those with hematologic malignancies and particularly patients who have undergone HCT
is not well described, and such patients are likely at greater risk of morbidity and mortality from COVID-19, underscoring the need for effective preventive and therapeutic strategies. To date, there is a paucity of data on the impact of COVID-19 on HCT recipients, and the reported cases have mainly described patients who developed COVID-19 after engraftment. 3-13

Overall, 276 HCT recipients with COVID-19 have been reported in the medical literature (Table 1). Of these, 171 (62%) were men and 105 (38%) women. The median age was 57 y (interquartile [IQR], 54-61). The median elapsed time from HCT to COVID-19 diagnosis was 309 d (IQR, 140-506). Of the 276 patients, 157 (57%) and 119 (43%) received an allogeneic HCT and an autologous HCT, respectively. Of the 157 allogeneic HCT recipients, 135 (86%) were on immunosuppressant drugs for chronic or acute GvHD at the time of COVID-19 diagnosis. Seventy-four of 276 patients (27%) had severe COVID-19 pneumonia and progressed to respiratory failure and ARDS. Overall mortality rate from COVID-19-related complications occurred in 48 (17%) patients. Of these, 30 (62%) and 18 (37%) patients had received an allogeneic and an autologous HCT, respectively.

To date, the only COVID-19 case reported in the pre-engraftment period was diagnosed at day +6 post HCT, and a detailed description of the clinical course during the engraftment phase was not provided. 4 Our two cases illustrate the impact of COVID-19 on HCT recipients during the pre-engraftment period and at the time of immune reconstitution. Although our autologous HCT recipient (Case 1) recovered without antiviral therapy, he received one dose of tocilizumab and a 4-day course of dexamethasone at the time of engraftment to abrogate the potential cytokine release and engraftment syndrome. Our allogeneic HCT recipient (Case 2) developed severe COVID-19 pneumonia and respiratory failure despite antiviral and immunomodulatory medications and corticosteroids. Of importance, there are similarities in immune recovery after allogeneic and autologous HCT; the timing of immune recovery can

FIGURE 2 Oxygen requirement, temperature curve, inflammatory markers, cell counts, and clinical course from time of transplant for patient 1 (top panel) and patient 2 (bottom panel). ALC: absolute lymphocyte count; CRP: C-reactive protein; FiO2: fraction of inspired oxygen; IL-6: interleukin-6; Toci: tocilizumab; Tmax: temperature maximum in Celsius; WBC: white blood cell count.
## TABLE 1  Characteristics of COVID-19 infections among hematopoietic cell transplantation recipients

| Ref. | Month/Year | No. of Pts. | Median age, yr | Gender | Type of Cancer | Medical Comorbidities | Type of HCT |
|------|------------|-------------|----------------|--------|----------------|-----------------------|-------------|
| 3    | June/2020  | 1           | 47             | M      | AITL           | None                  | Allo/MUD    |
| 4    | July/2020  | 7           | 61             | F (5), M (2) | AML (3), MDS (1), MF (1), B-ALL (1), HL (1) | HTN (1), obesity (2), DM (1) | Allo (6) [MUD (4), Haplo (2)]; Auto (1) |
| 5    | July/2020  | 1           | 59             | M      | MF            | DM                    | Allo/MRD    |
| 6    | June/2020  | 2           | 60             | F (1), M (1) | B-ALL (1), AML (1) | CAD + HTN + COPD + obesity (1) | Allo (2) [Haplo (1), MUD (1)] |
| 7    | May/2020   | 7           | 61             | F (2), M (5) | MM (5), ALL (1), DLBCL (1) | HTN (2); DM + HTN + obesity (2); CM (1); HTN + stroke (1) | Auto (5), Allo (2) |
| 8    | Aug/2020   | 34          | 57             | F (12), M (22) | AL (16), MM (9), Lym (6), others (3) | Obesity (11), smoking (20), HTN (15), DM (13) | Auto (14); Allo (20) |
| 9    | Aug/2020   | 2           | 57             | F (2) | CML (1), AML (1) | HTN (2) | Allo (2) [MRD (1), MUD (1)] |
| 10   | Dec/2020   | 72          | 62             | M (46), F (26) | MM (28), NHL (15), A/C L (19), MDS (4), HL (4), AL (1), MPD (1) | 1\(^a\) 2 + 6 | Allo (35) [MRD (9), MUD (8), MisMUD (7), UCB (7), Haplo (4)]; Auto (37) |
| 11   | Oct/2020   | 113         | 54             | M (64), F (49) | NR | NR | Allo (71), Auto (42) |
| 12   | Oct/2020   | 32          | 56             | M (25), F (7) | MM (11), NHL (7), HL (2), AML (5), ALL (3), CML (3), AA (1) | DM (7), HTN (18), CAD (5), Respiratory diseases (10) | Allo (12) [MRD (9), MUD (3)], Auto (20) |
| 13   | Nov/2020   | 5           | 30             | M (4), F (1) | AA (1), AML (2), ALL (2) | NR | Allo (5) [MRD (5)] |

Abbreviation: AA: aplastic anemia; AITL: angioimmunoblastic T-cell lymphoma; AL: acute leukemia; A/C L: acute/chronic leukemia; AL: AL amyloidosis; ALL: acute lymphoblastic leukemia; Allo: allogeneic; AML: acute myeloblastic leukemia; A,M, An: anakinra; ARDS: acute respiratory distress syndrome; Aug: August; Auto: autologous; AZT: azithromycin; BEAM: carmustine + etoposide + cytarabine + melphalan; Bu/Flu/Alem: busulfan/fludarabine/alemtuzumab; CCP: convalescent plasma; CG: corticosteroids; CLL: chronic lymphoblastic leukemia; CM: cardiomyopathy; CML: chronic myeloblastic leukemia; CNI: calcineurin inhibitors; Cond. Reg.: conditioning regimen; COPD, chronic obstructive pulmonary disease; Cyclo: cyclosporine; Dec: December; DLBCL: diffuse large B-cell lymphoma; DM: diabetes mellitus; dys: dyslipidemia; F: female; Haplo: haploidentical; Haplo: haploidentical; HCO: hydroxychloroquine; HL: Hodgkin lymphoma; HTN: arterial hypertension; ISD: immunosuppressant drugs (not specified); Lop/r: lopinavir/ritonavir; Lym: lymphoma; M: male; MAC: myeloablative regimen; MDS: myelodysplastic syndrome; MM: myelofibrosis; MMF: mycophenolate mofetil; MPD: myeloproliferative disorder; MRD: matched related donor; mTOR: mTOR inhibitors; MUD: matched unrelated donor; MisMUD: mismatched unrelated donor; MTX: methotrexate; N/A: not applicable; Nov: November; NR: not reported; Pt: patient; PTCy: post-transplant cyclophosphamide; Prog: progression; Oct: October; Ref: reference; Remd: remdesivir; Rib, ribavirin; RIC: reduced intensity conditioning regimen; Rit: rituximab; Rxu: ruxolitinib; Tacro: tacrolimus; Toci: tocilizumab; UCB: umbilical cord blood.

\(^a\)Comorbidities include hypertension, congestive heart failure, chronic obstructive pulmonary disease, diabetes mellitus, HIV, and chronic kidney disease.
| Primary Prophylaxis | Cond. Reg./GvHD | rRT-PCR | Median time from HCT, days | GVHD Treatment | Prog. to ARDS | Treatment | Outcome |
|---------------------|----------------|--------|--------------------------|---------------|-------------|-----------|---------|
| NR                  | Yes            |        | 510                      | Rux           | No          | HCQ       | Alive   |
| Non-MAC (5)/PTCy (4); Bu/Flu/Alem (1); BEAM (1) | Yes (7) | 98 | Tacro + MMF (2); Tacro (1); CG + infliximab (1); CG (1) | Yes (2) | HCQ (1) | Alive (4); Dead (3) [Allo (2), Auto (1)] |
| NR                  | Yes            | 379    | Rux                      | Yes           | Lop/r, HCQ  | Alive     |
| MAC + PCTy (1); Non-MAC (1) | No [CRISPR (2)] | 238 | CG/Ritu (2); ibritunib (1) | Yes (1) | CCP (1) | Alive (1), Dead (1) |
| NR (7)              | Yes (7)        | NR (7) | NR (2)                   | Yes (3) [Allo (2)] | Ana (1); Lop/r (1); HCQ/AZT + Toci (1) | Dead (1) [Auto] |
| MAC (21)            | Yes (34)       | 529    | ISD (15)                 | Yes (14)      | HCQ (15), Toci (6), Remd (5), CCP (2), Lop/r (1), Ana (1), sarilumab (1), Rib (1) | Alive (27); Dead (7) [Allo (5), Auto (2)] |
| MAC (2)             | Yes (2)        | 107    | CG + Cyclo (1); MMF + Cyclo (1) | No            | HCQ (2), AZT (1) | Alive     |
| MAC (13), Non-MAC (5), RIC (17), PTCy (7) | Yes (72) | N/A   | CNI/MMF (9); CNI/MTX (10) | Yes (15) | HCQ (23), AZT (18), Methylp (13), CCP (11), Toci (7), Remd (3) | Dead (13) [ Allo (9), Auto (4)] |
| NR                  | Yes            | 495    | CNI (23), MMF (4), mTOR (8), CG (44) | Yes (26) | HCQ (74), AZT (33), CG (22), Toci (19), Anakinra (3) | Dead (18) [ Allo (11), Auto (7)] |
| NR                  | Yes            | NR     | Cyclo (4), Tacro (2)     | Yes (11) | Lop/r (2), HCQ (24), Favipiravir (12), Oseltamivir (12) | Dead (5) [Allo (2), Auto (3)] |
| MAC (5), PTCy (3)   | Yes            | 240    | Cyclo (4) + CG (4), MMF (1) | Yes (1) | CG (1) | Alive (5) |
be affected by many factors, such as the source of stem cells, the degree of human leukocyte antigen match, and the use of immunosuppressant drugs, including corticosteroids, that could affect the immune reconstitution. Recovery of the immune system occurs gradually over the post-transplantation period.\textsuperscript{16} The first immune cells to engraft are monocytes, followed by granulocytes, platelets, and natural killer cells, which together constitute the innate immunity. In contrast, adaptive immunity, consisting of B and T lymphocytes, may take 1-2 y to full recover.\textsuperscript{16} Also, engraftment syndrome is more prevalent among allogeneic HCT recipients and occurs at the time of neutrophil recovery; it can be associated with poor prognosis.\textsuperscript{17,18} It is possible that our second patient developed a concurrent engraftment syndrome with COVID-19 pneumonia that led to respiratory failure and ARDS. Therefore, it is crucial to identify high-risk patients who may benefit from early preemptive treatment strategies such as antiviral therapy. It is noteworthy that two reported patients were receiving ruxolitinib for chronic GvHD treatment at the time of COVID-19 infection; one patient had an attenuated course of infection, and the other patient had ARDS but after resuming ruxolitinib, remarkable improvement, and recovery occurred.\textsuperscript{3,5} Given this observation, the role of ruxolitinib has gained attention since it is characterized not only by immunosuppressive activity but also by anti-inflammatory effects with the potential role of dampening the cytokine release syndrome; importantly, a clinical trial evaluating ruxolitinib as novel therapy for COVID-19 pneumonia is ongoing (NCT04338958).\textsuperscript{19}

On the other hand, a cohort study by Kuderer et al reported a 30-day all-cause mortality of 13% in patients with cancer and COVID-19, including patients with hematologic malignancies, which was higher than the mortality rate reported in the general population.\textsuperscript{20,21} However, based on our current review, the mortality rate in HCT recipients is quite high (17%). Therefore, preventive measures remain the best approach for reducing the burden of COVID-19 infections in HCT recipients, and strict adherence to infection control measures and increased awareness among patients, caregivers, and health-care personnel are critical. Another important clinical aspect to be considered is that the immune recovery during engraftment may lead to severe COVID-19 pneumonia secondary to exuberant inflammatory response that may require early therapy such as remdesivir and/or steroids before decompensation. Considering the substantial comorbidities and mortality among cancer patients with COVID-19, notably in HCT recipients, novel therapeutic and preventive strategies are of utmost importance.

CONFLICTS OF INTEREST
All authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
AEM, JAA, VEM, JS, IIR, KM, GTS, UD, FK, and RFC wrote the manuscript draft and revised the manuscript; JAA, VEM, KM, GT, and UD were involved in patients treatment. All the authors approved the final version of the manuscript.

DATA AVAILABILITY STATEMENT
Data sharing not applicable – no new data generated.

ORCID
Alexandre E. Malek \url{https://orcid.org/0000-0002-7867-4502}

REFERENCES
1. World Health Organization. Novel coronavirus-China. January 12, 2020. Available online: https://covid19.who.int/. Accessed December 31\textsuperscript{st}, 2020.
2. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451-1454.
3. Foss FM, Rubinowitz A, Landry ML, et al. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clin Lymphoma Myeloma Leuk. 2020;20(11):720-723.
4. Kanellopoulos A, Ahmed MZ, Kishore B, et al. COVID-19 in bone marrow transplant recipients: reflecting on a single centre experience. Br J Haematol. 2020;190(2):e67-e70.
5. Saraceni F, Scortechini I, Mancini G, et al. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib. Transpl Infect Dis. 2020;23(1):e13401.
6. Niu A, McDougall A, Ning BO, et al. COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma. Bone Marrow Transplant. 2020;55(12):2354-2356.
7. Malard F, Genthon A, Brisot E, et al. COVID-19 outcomes in recipients of hematopoietic cell transplantation: the Spanish experience. Am J Transplant. 2020;20(12):6656-6667.
8. Varma A, Kosuri S, Ustun C, et al. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter. Leukemia. 2020;34(10):2809-2812.
9. Hatzi S, Eisner F, Schilcher G, et al. Response to “COVID-19 in persons with haematological cancers”. Leukemia. 2020;34(8):2265-2270.
10. Shah GL, DeWolf S, Lee YJ, et al. Favorable outcomes of COVID-19 in patients with hematologic disease. Bone Marrow Transplant. 2020;55(11):2180-2184.
11. Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, et al. COVID-19 in transplant recipients: The Spanish experience. Am J Transplant. 2020. https://doi.org/10.1111/ajt.16369
12. Altuntas F, Ate N, Yigenoglu TN, et al. COVID-19 in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2020. https://doi.org/10.1038/s41409-020-01084-x
13. Sultan AM, Mahmoud HK, Fathy GM, Abdelfattah NM. The outcome of hematopoietic stem cell transplantation patients with COVID-19 infection. Bone Marrow Transplant. 2020. https://doi.org/10.1038/s41409-020-01094-9
14. Guan W-J, Ni Z-Y, Hu YU, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
15. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337.
16. Storek J, Geddes M, Khan F, et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol. 2008;30(4):425-437.
17. Spitzer TR. Engraftment syndrome: Double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50(4):469-475.
18. Chang L, Frame D, Braun T, et al. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014;20(9):1407-1417.
19. La Rosée F, Bremer HC, Gehrke I, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020;34(7):1805-1815.

20. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918.

21. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020;20(7):773.